Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: risk factors for accelerated macrovascular damage? by Szamosi, Szilvia et al.
AUTHOR'S PROOF
Metadata of the article that will be visualized online 
  
  
1 Article Title Plasma Homocysteine Levels, The Prevalence of 
Methylenetetrahydrofolate Reductase Gene C677T Polymorphism 
and Macrovascular Disorders in Systemic Sclerosis: Risk Factors 
for Accelerated Macrovascular Damage? 
2 Article Sub- Title 
3 Article Copyright - 
Year 
Humana Press Inc. 2008 
(This will be the copyright line in the final PDF) 
4 Journal Name Clinical Reviews in Allergy & Immunology 
5 
Corresponding 
Author 
Family Name Szekanecz 
6 Particle 
7 Given Name Zoltán 
8 Suffix 
9 Organization University of Debrecen, Medical and Health Science 
Centre 
10 Division Division of Rheumatology, Third Department of 
Internal Medicine 
11 Address Hungary Móricz Zs krt. 22., Debrecen 4004, Hungary 
12 e-mail Szekanecz@hotmail.com 
13 
Author 
Family Name Szamosi 
14 Particle 
15 Given Name Szilvia 
16 Suffix 
17 Organization University of Debrecen, Medical and Health Science 
Centre 
18 Division Division of Rheumatology, Third Department of 
Internal Medicine 
19 Address Hungary Móricz Zs krt. 22., Debrecen 4004, Hungary 
20 e-mail 
21 
Author 
Family Name Csiki 
22 Particle 
23 Given Name Zoltán 
24 Suffix 
25 Organization University of Debrecen, Medical and Health Science 
Centre 
26 Division Division of Rheumatology, Third Department of 
Internal Medicine 
27 Address Hungary Móricz Zs krt. 22., Debrecen 4004, Hungary 
28 e-mail 
29 Family Name Szomják 
30 Particle 
Page 1 of 3Testsite
11/26/2008file://C:\Programs\Metadata\temp\rai88105.htm
AUTHOR'S PROOF
Author 
31 Given Name Edit 
32 Suffix 
33 Organization University of Debrecen, Medical and Health Science 
Centre 
34 Division Division of Rheumatology, Third Department of 
Internal Medicine 
35 Address Hungary Móricz Zs krt. 22., Debrecen 4004, Hungary 
36 e-mail 
37 
Author 
Family Name Szolnoki 
38 Particle 
39 Given Name Erzsébet 
40 Suffix 
41 Organization University of Debrecen, Medical and Health Science 
Centre 
42 Division Division of Rheumatology, Third Department of 
Internal Medicine 
43 Address Hungary Móricz Zs krt. 22., Debrecen 4004, Hungary 
44 e-mail 
45 
Author 
Family Name Szıke 
46 Particle 
47 Given Name Gabriella 
48 Suffix 
49 Organization University of Debrecen Medical and Health Science 
Center 
50 Division Department of Clinical Biochemistry and Molecular 
Pathology 
51 Address Debrecen , Hungary 
52 e-mail 
53 
Author 
Family Name Szegedi 
54 Particle 
55 Given Name Gyula 
56 Suffix 
57 Organization Hungarian Academy of Sciences 
58 Division Research Center for Autoimmune Diseases 
59 Address Debrecen , Hungary 
60 e-mail 
61 
Author 
Family Name Shoenfeld 
62 Particle 
63 Given Name Yehuda 
64 Suffix 
65 Organization Sheba Medical Center 
66 Division Department of Medicine B and Center for 
Autoimmune Diseases 
Page 2 of 3Testsite
11/26/2008file://C:\Programs\Metadata\temp\rai88105.htm
AUTHOR'S PROOF
67 Address Tel-Hashomer , Israel 
68 e-mail 
69 
Author 
Family Name Szőcs 
70 Particle 
71 Given Name Gabriella 
72 Suffix 
73 Organization University of Debrecen, Medical and Health Science 
Centre 
74 Division Division of Rheumatology, Third Department of 
Internal Medicine 
75 Address Hungary Móricz Zs krt. 22., Debrecen 4004, Hungary 
76 e-mail 
77 
Schedule 
Received   
78 Revised   
79 Accepted   
80 Abstract The purpose of this study was to investigate plasma homocysteine (Hcy) levels 
in patients with systemic sclerosis (SSc) and to study the association between 
plasma Hcy, C677T polymorphism of 5,10-methylenetetrahydrofolate reductase 
(MTHFR), and the clinical manifestations in SSc. Associations of Hcy level, 
C677T MTHFR polymorphism, and macrovascular diseases were investigated 
in 152 patients with SSc and 58 controls. No significant differences in Hcy 
levels and MTHFR genotypes were found in SSc patients compared to controls 
or in SSc patients with limited cutaneous compared to diffuse disease. 
Significantly higher Hcy concentration was observed in patients with 
macroangiopathy/thromboembolic events compared to patients without such 
clinical manifestations (p < 0.05). There was significant correlation between age 
and macrovascular disorders, between Hcy level and the disease duration (r = 
0.164; p < 0.05). Seventy-one percent of patients with macrovascular disorders 
had MTHFR polymorphism. In addition, 45% of patients with 
hyperhomocysteinemia had pulmonary hypertension. The presence of MTHFR 
C677T mutation influences the incidence of macrovascular abnormalities in SSc 
patients. Elevated Hcy levels may be associated with disease duration and the 
evolution of macrovascular disorders and pulmonary hypertension in SSc. 
81 Keywords 
separated by ' - ' 
Systemic sclerosis - Folate - Homocysteine - Vascular disease 
82 Foot note 
information 
This work was supported by the National Foundation for Scientific Research 
(OTKA T 032947) (G.S.) 
Page 3 of 3Testsite
11/26/2008file://C:\Programs\Metadata\temp\rai88105.htm
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
1
2
3
4 Plasma Homocysteine Levels, The Prevalence
5 of Methylenetetrahydrofolate Reductase Gene C677T
6 Polymorphism and Macrovascular Disorders in Systemic
7 Sclerosis: Risk Factors for Accelerated Macrovascular
8 Damage?
9 Szilvia Szamosi & Zoltán Csiki & Edit Szomják &
10 Erzsébet Szolnoki & Gabriella Szőke & Zoltán Szekanecz &
11 Gyula Szegedi & Yehuda Shoenfeld & Gabriella Szűcs
12
13 # Humana Press Inc. 2008
14
15 Abstract The purpose of this study was toQ1 investigate
16 plasma homocysteine (Hcy) levels in patients with systemic
17 sclerosis (SSc) and to study the association between plasma
18 Hcy, C677T polymorphism of 5,10-methylenetetrahydrofolate
19 reductase (MTHFR), and the clinical manifestations in SSc.
20 Associations of Hcy level, C677T MTHFR polymorphism,
21 and macrovascular diseases were investigated in 152 patients
22 with SSc and 58 controls. No significant differences in Hcy
23 levels and MTHFR genotypes were found in SSc patients
24compared to controls or in SSc patients with limited cutaneous
25compared to diffuse disease. Significantly higher Hcy con-
26centration was observed in patients with macroangiopathy/
27thromboembolic events compared to patients without such
28clinical manifestations (p<0.05). There was significant
29correlation between age and macrovascular disorders, be-
30tween Hcy level and the disease duration (r=0.164; p<0.05).
31Seventy-one percent of patients with macrovascular disorders
32had MTHFR polymorphism. In addition, 45% of patients
33with hyperhomocysteinemia had pulmonary hypertension.
34The presence of MTHFR C677T mutation influences the
35incidence of macrovascular abnormalities in SSc patients.
36Elevated Hcy levels may be associated with disease duration
37and the evolution of macrovascular disorders and pulmonary
38hypertension in SSc.
39Keywords Systemic sclerosis . Folate . Homocysteine .
40Vascular disease
41Introduction
42Systemic sclerosis (SSc) is associated with endothelial cell
43dysfunction, where classically the microvasculature is
44affected. Recently, it is recognized that large-vessel disease
45also occurs with higher incidence [1–2].
46Hyperhomocysteinemia predisposes to atherosclerosis
47by injuring the vascular endothelium. A genetic cause of
48hyperhomocysteinemia is due to a mutation in the 5,10-
49methylenetetrahydrofolate reductase (MTHFR) gene. A
50thermolabile variant of this enzyme, due to a point mutation
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51 677°C to T changing alanine to valine, has been correlated
52 with elevated plasma homocysteine (Hcy) levels [3].
53 Considering these data, we hypothesized that hyperhomo-
54 cysteinemia may play a role in the pathogenesis of micro- and
55 macrovascular damage underlying SSc. Therefore we inves-
56 tigated the frequency of hyperhomocysteinemia in SSc and
57 analyzed the association of plasma Hcy levels, MTHFR
58 C677T mutation, and clinical manifestations in our patients
59 compared to healthy subjects.
60 Methods
61 Patients One hundred fifty-two SSc patients (131 lcSSc, 21
62 dcSSc) were included in our study (all satisfied the
63 American College of Rheumatology criteria for SSc [4,
64 5]; mean age, 54.2 years; mean disease duration, 9.61
65 years; 133 females; 19 males). The classification of the
66 patients’ disease as diffuse or limited (dcSSc or lcSSc) was
67 established according to Le Roy et al. [5]. Patients with
68 skin sclerosis limited to hands, forearms, legs below the
69 knee, and face were defined as having limited cutaneous
70 scleroderma (lcSSc). Those with more extensive skin
71 disease spreading proximal to elbows or knees or involving
72 the trunk were classified as diffuse cutanous scleroderma
73 (dcSSc). (The onset of disease was defined as the beginning
74 of Raynaud’s phenomenon (RP) or awareness of numbness,
75 puffiness or sclerosis of fingers without preceding RP.
76 Pulmonary involvement (pulmonary fibrosis or alveolitis)
77 was defined as present by radiographic findings including
78 X-ray and HRCT, as well as pulmonary function tests.
79 Esophageal involvement was assessed by barium swallow
80 test (esophageal dismotility). Cardiac involvement includ-
81 ing relaxation and/or conduction disturbances, right ven-
82 tricular hypertrophy were assessed by 2-D as well as
83 Doppler echocardiography and ECG. For comparison, we
84 studied 58 age- and sex-matched healthy controls (mean
85 age, 49.9 years; 46 females and 12 males).
86 Laboratory tests Total Hcy levels were measured with high-
87 performance liquid chromatography method (BIO-RAD,
88 Hercules, CA, USA) [6]. The upper limit of the normal
89 range of total plasma homocysteine was 12.5 μmol/l.
90 The C677T mutation of the MTHFR gene was assessed
91 by DNA-fragmentation using specific restriction endonu-
92 clease enzyme followed by PCR amplification and agarose
93 gel electrophoresis [7]. Patients and controls were geno-
94 typed as homozygous for the mutation (TT), heterozygous
95 (CT), or wild-type (CC).
96 Statistical analysis Statistical analysis included paired t
97 test, Mann–Whitney U test, calculation of Spearman’s
98 correlation coefficient, and Chi-square test was applied to
99compare parameters in different groups. p values<0.05
100were considered significant. 1
102Results
103Seventy-eight percent of SSc patients had pulmonary, 57%
104had esophageal and 39% had myocardial involvement,
105while 9.8% of the patients Q1had pulmonary hypertension
106(PAH) as screened by Doppler echocardiography. PAH was
107considered present if the estimated right ventricular systolic
108pressure exceeded 45 mmHg. Twenty percent of SSc
109patients had macrovascular manifestations (24 lcSSc, seven
110dcSSc). Twenty-six of 31 patients (84%) had obliterative
111arteriosclerosis of lower extremities, eight (26%) had
112coronary heart disease, two (6.4%) had stroke, and three
113(9.7%) had deep venous thrombosis. Macrovascular dis-
114eases of SSc patients and cardiovascular risk factors
115(hypertension, diabetes mellitus, hyperlipoproteinemia,
116and smoking) showed no strong correlation except between
117hypertension and cerebral stroke. Main cardiovascular risk
118factors of patients and controls are shown in Table 1.
119The mean plasma Hcy levels were 9.3 μmol/l in SSc and
12010.1 μmol/l in controls. There were no significant differ-
121ences in the Hcy levels between SSc and controls or
122between lcSSc or dcSSc subtypes.
123Analyzing theMTHFR genotypes, no statistical differences
124were found between SSc patients and controls. Forty-nine
125percent of patients showed wild, 36% heterozygous, and 15%
126homozygous MTHFR genotypes while 40% of controls had
127wild, 47% heterozygous, and 13% homozygous genotypes.
128There were no significant differences in Hcy levels between
129homozygous, heterozygous, and wild genotype within the Ssc
130and control group.
131Analyzing correlations between Hcy levels and macro-
132angiopathic/thromboembolic events in SSc we found signifi-
133cantly higher Hcy concentrations in patients with
134macroangiopathic/thromboembolic events (10.5±7.1 μmol/l)
135compared to patients without such clinical manifestations (9.1±
1367.6 μmol/l) (Fig. 1). Six of 31 patients with macroangiopathy/
137thromboembolic events (19%) had homozygous (TT)
t1.1Table 1 Main cardiovascular risk factors of SSc patients and controls
Risk factors Systemic sclerosis
(152)
Control
(58) t1.2
BMI (kg/m2) 22.8±2.6 24.7±4.8 t1.3
Hypertension 15 (9.8%) – t1.4
Diabetes mellitus 6 (3.9%) – t1.5
Hyperlipoproteinemia 20 (13%) 6 (10.3%) t1.6
Smoking 1 (0.6%) 8 (13.7%) t1.7
Family history of
cardiovascular disease
34 (22.37%) 20 (34.48%) t1.8
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138 MTHFR variants, 16 (52%) had heterozygous (CT), and nine
139 (29%) had wild type (CC).
140 A significant correlation was found between the age of
141 SSc patients and the existence of macrovascular disorders
142 (Fig. 2). Finally, a positive correlation was observed
143 between plasma Hcy levels and the disease duration of
144 SSc (r=0.164, p=0.043). In addition, the presence of
145 macrovascular abnormalities in SSc patients was associated
146 with longer disease duration (Fig. 3).
147 Analyzing the clinical parameters, prevalence of pulmonary
148 hypertension was elevated in our patients who had higher than
149 15 μmol/l plasma Hcy concentration. Ten of 22 patients with
150Hcy concentration >15 μmol/l had pulmonary hypertension
151(45%). In total SSc patients there were only 15 patients (9.8%)
152with pulmonary hypertension. There was no correlation
153between Hcy concentration and other clinical or serological
154parameters.
155Discussion
156SSc is a vascular disease, where the microvasculature is
157affected. In recent years increased attention has been paid to
158the importance of large vessel involvement in SSc [2].
159Increased plasma Hcy concentration is an independent risk
160factor for macrovascular disorders and it may be associated
161with an increased risk of small-vessel thrombosis also [7].
162In the present study, we did not find significant differences
163in Hcy levels and MTHFR polymorphism between SSc
164patients as well as healthy controls lacking any vascular
165disease, although impaired endothelial function in hyper-
166homocysteinemia is well known [8]. The frequency of
167C677T variant of MTHFR gene in our results are similar to
168other reports where the homozygous form was found in
169about 10–13% and the heterozygous form in about 45% of
170Caucasian people [9].
171Assessing the relationship between Hcy levels and the
172occurrence of macroangiopathic/thromboembolic events in
173SSc patients, we found significantly higher Hcy concen-
174trations in patients with vascular/thromboembolic events in
175comparison to SSc patients without such manifestations.
176Altogether, 71% of patients with macrovascular disorders
177had either homozygous (TT) or heterozygous (CT) MTHFR
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178 variants. These data suggest that the existence of MTHFR
179 C677T mutation (TT or CT form), may influence the
180 incidence of macrovascular abnormalities in SSc. Although it
181 is the microvasculature that is primarily affected in patients
182 with SSc, it is recognized that large-vessel disease also occurs
183 with higher incidence and the involvement of the macro-
184 vasculature may be involved in the outcome of SSc [2].
185 Considering these results and data previously reported by
186 others, which could not identify MTHFR gene polymor-
187 phism as an independent risk factor for vascular complica-
188 tions in macrovascular diseases, we can conclude that there
189 are other risk factors that may be crucial for the development
190 of macrovascular manifestations in SSc [10–11].
191 We found a positive correlation between age and the
192 existence of macrovascular manifestations in SSc. Besides
193 there was a significant correlation between disease duration
194 and the development of macrovascular manifestations.
195 These results suggest that macrovascular disease is not
196 only an age-related feature in SSc but may also depend on
197 disease-associated mechanisms. Finally, prevalence of
198 pulmonary hypertension was elevated in 45% of our
199 patients who had >15 μmol/l plasma Hcy concentration,
200 which may have relevance for clinical practice.
201 In summary, our results suggest that hyperhomocysteinemia
202 and the polymorphism of MTHFR gene may be involved in the
203 vascular damage associated with SSc and further prospective
204 studies are needed to clarify their role in endothelial dysfunction.
205 We acknowledge that the data require further effort and
206 recapitulation in a larger series, but we also note the critical
207 contribution of genetics in other autoimmune situations [12–26].
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